CN100430061C - 内过氧化物在制备治疗由黄病毒科病毒(包括丙型肝炎病毒、牛病毒性腹泻病毒和猪瘟病毒)引起的感染的药物中的应用 - Google Patents

内过氧化物在制备治疗由黄病毒科病毒(包括丙型肝炎病毒、牛病毒性腹泻病毒和猪瘟病毒)引起的感染的药物中的应用 Download PDF

Info

Publication number
CN100430061C
CN100430061C CNB2003801026935A CN200380102693A CN100430061C CN 100430061 C CN100430061 C CN 100430061C CN B2003801026935 A CNB2003801026935 A CN B2003801026935A CN 200380102693 A CN200380102693 A CN 200380102693A CN 100430061 C CN100430061 C CN 100430061C
Authority
CN
China
Prior art keywords
virus
artemisinin
hepatitis
endoperoxides
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB2003801026935A
Other languages
English (en)
Chinese (zh)
Other versions
CN1711091A (zh
Inventor
扬·范登凯尔克霍弗
贝内迪克特·萨斯
埃里克·派斯
约翰·范赫梅尔
约翰·内叶茨
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kemin Foods LC
Original Assignee
Kemin Foods LC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kemin Foods LC filed Critical Kemin Foods LC
Publication of CN1711091A publication Critical patent/CN1711091A/zh
Application granted granted Critical
Publication of CN100430061C publication Critical patent/CN100430061C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A61K36/282—Artemisia, e.g. wormwood or sagebrush
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CNB2003801026935A 2002-10-31 2003-10-29 内过氧化物在制备治疗由黄病毒科病毒(包括丙型肝炎病毒、牛病毒性腹泻病毒和猪瘟病毒)引起的感染的药物中的应用 Expired - Fee Related CN100430061C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42268302P 2002-10-31 2002-10-31
US60/422,683 2002-10-31

Publications (2)

Publication Number Publication Date
CN1711091A CN1711091A (zh) 2005-12-21
CN100430061C true CN100430061C (zh) 2008-11-05

Family

ID=32312544

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB2003801026935A Expired - Fee Related CN100430061C (zh) 2002-10-31 2003-10-29 内过氧化物在制备治疗由黄病毒科病毒(包括丙型肝炎病毒、牛病毒性腹泻病毒和猪瘟病毒)引起的感染的药物中的应用

Country Status (11)

Country Link
US (1) US7842719B2 (https=)
EP (1) EP1585524B1 (https=)
JP (1) JP4594734B2 (https=)
CN (1) CN100430061C (https=)
AT (1) ATE473745T1 (https=)
AU (1) AU2003287259A1 (https=)
CA (1) CA2501584C (https=)
DE (1) DE60333392D1 (https=)
ES (1) ES2348536T3 (https=)
PT (1) PT1585524E (https=)
WO (1) WO2004041176A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112294795A (zh) * 2020-11-17 2021-02-02 北京化工大学 蒿甲醚在治疗和预防柯萨奇病毒感染中的应用

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3257509A1 (en) 2003-02-12 2017-12-20 Georgetown University Use of artemisinin and related compounds for treating anorectal squamous cell cancer induced by human papilloma virus
ES2245248B1 (es) * 2004-06-09 2007-02-16 Universidad De Salamanca Uso de la artemisinina y sus derivados en la fabricacion de medicamentos utiles como agentes antiviricos.
KR100824106B1 (ko) * 2006-05-30 2008-04-21 주식회사 씨티씨바이오 흰반점바이러스를 치료 또는 예방하기 위한 조성물 및 방법
WO2008010620A1 (en) * 2006-07-21 2008-01-24 Ben's Lab Co., Ltd. Composition comprising the crude drug extracts for improving liver function
BRPI0715714A2 (pt) * 2006-08-25 2014-03-11 Wyeth Corp Métodos para diminuir a frequência de emergência de uma infecção viral de hepatite c resistente ao tratamento, para atrasar a emergência de uma infecção viral de hepatite c resistente ao tratamento, para diminuir o nível de resistência de uma infecção viral de hepatite c resistente ao tratamento, para diminuir a emergência de uma infecção viral de hepatite c resistente a hcv-796, para identificar um indivíduo com uma probabilidade diminuída de responder a uma terapia viral anti-hepatite c, para monitorar, diagnosticar ou prognosticar a infecção viral de hepatite c resistente ao tratamento em um paciente, para monitorar o curso de tratamento de uma infecção viral de hepatite c em um paciente, para prognosticar o desenvolvimento de um ainfecção viral de hepatite c resistente ao tratamento em um paciente, para monitorar a infecção viral de hepatite c em um paciente e para diagnosticar o desenvolvimento de uma infecção viral de hepatite ao tratamento em um paciente
EP2310393A4 (en) * 2008-06-17 2011-06-22 Hhv 6 Foundation ARTEMISININE AND DERIVATIVES THEREOF AS ANTIVIRAL AGENTS
CN102731464B (zh) * 2011-04-12 2014-07-23 沈阳药科大学 一个倍半萜内酯化合物、制备方法及其应用
US20130012470A1 (en) * 2011-07-07 2013-01-10 Humanitas Technology, LLC Antiviral compositions and methods of their use
US20130028882A1 (en) 2011-07-07 2013-01-31 Humanitas Technology, LLC Antiviral compositions and methods of their use
BR112014026158A2 (pt) * 2012-04-18 2017-06-27 Hadasit Med Res Service métodos e composições para o tratamento de infecções virais
FR2989588A1 (fr) * 2012-04-19 2013-10-25 Centre Nat Rech Scient Composes pour la prevention ou le traitement des infections par des virus de la famille des flaviviridae
CN102755316A (zh) * 2012-07-16 2012-10-31 中国科学院武汉病毒研究所 青蒿素及其衍生物在制备治疗丙型肝炎病毒药物中的应用
CN110139655A (zh) * 2016-10-07 2019-08-16 纳维迪亚生物制药有限公司 诊断和治疗病毒性感染的化合物和方法
GB201805665D0 (en) * 2018-04-05 2018-05-23 Univ Nottingham Antiviral Compounds And Methods
WO2019232129A1 (en) * 2018-05-30 2019-12-05 The Board Of Regents Of The University Of Texas System Treatment of viral infections and virally associated lesions with sequiterpene lactones
WO2021216385A1 (en) * 2020-04-20 2021-10-28 Tran Lloyd Hung Loi Methods for the prophylaxis and treatment of covid and covid-19
CN112245424B (zh) * 2020-10-19 2021-09-21 中国医学科学院医药生物技术研究所 一种没药烷倍半萜结构类似物在制备抗冠状病毒药物中的用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0456149A1 (en) * 1990-05-07 1991-11-13 Hoechst Aktiengesellschaft 9-Substituted compounds of 3 alpha, 11 alpha-Epoxy-3,4,5, 5a alpha,6,7,8,8a,9,11,11a-undecahydro-3 beta, 6 alpha, 9-trimethylfurano[3,4-j][1,2]-benzodioxepin, processes for their preparation and their use as antiprotozoal and antiviral agents
CN1105238A (zh) * 1992-11-10 1995-07-19 中国预防医学科学院病毒学研究所 抗aids病毒的药物组合物
CN1035767C (zh) * 1992-11-10 1997-09-03 罗宣德 新的青蒿素衍生物及其用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1058717A (zh) * 1990-08-08 1992-02-19 中国人民解放军军事医学科学院微生物流行病研究所 抗疟新药—复方蒿甲醚及其制备方法
US5726203A (en) * 1993-07-19 1998-03-10 Li; Zelin Qinghaosu derivatives against AIDS
DE4415539C2 (de) * 1994-05-03 1996-08-01 Osama Dr Dr Med Omer Pflanzen mit virustatischer und antiviraler Wirkung
CN1049435C (zh) * 1994-11-09 2000-02-16 中国科学院上海药物研究所 含苯基和杂环基的青蒿素衍生物及其制备方法
DE19902924A1 (de) 1999-01-26 2000-08-03 Hassan Jomaa Verwendung von phosphororganischen Verbindungen zur prophylaktischen und therapeutischen Behandlung von Infektionen
CN1135974C (zh) 2000-08-23 2004-01-28 重庆健桥医药开发有限公司 抗疟药新药复方双氢青蒿素
AU2001295979A1 (en) 2000-10-20 2002-04-29 Ajinomoto Co., Inc. Medicinal compositions, dose and method for treating malaria
EP3257509A1 (en) * 2003-02-12 2017-12-20 Georgetown University Use of artemisinin and related compounds for treating anorectal squamous cell cancer induced by human papilloma virus

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0456149A1 (en) * 1990-05-07 1991-11-13 Hoechst Aktiengesellschaft 9-Substituted compounds of 3 alpha, 11 alpha-Epoxy-3,4,5, 5a alpha,6,7,8,8a,9,11,11a-undecahydro-3 beta, 6 alpha, 9-trimethylfurano[3,4-j][1,2]-benzodioxepin, processes for their preparation and their use as antiprotozoal and antiviral agents
CN1105238A (zh) * 1992-11-10 1995-07-19 中国预防医学科学院病毒学研究所 抗aids病毒的药物组合物
CN1035767C (zh) * 1992-11-10 1997-09-03 罗宣德 新的青蒿素衍生物及其用途

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
Cis-acting RNA elements required for replication of bovine.Viral diarrhea virus-hepatitis C virus 5' non-translated regionchimeras. Frolov l., McBride S., Rice C. M.RNA,Vol.4. 1998 *
RT-PCR技术在流行性出血热病毒分型诊断中的应用. 张淑玲，郑曲波，曾令兰.临床内科杂志，第17卷第4期. 2000 *
丙型肝炎病毒的分子生物学研究进展. 王海林，金冬燕.中华实验和临床病毒学杂志，第9卷第1期. 1995 *
病毒命名与分类系统研究进展. 徐耀先，解梦霞，向近敏.中国病毒学，第14卷第3期. 1999 *
边界病. 杨林，张绍学，牛钟相，王新平.山东农业大学学报，第30卷第1期. 1999 *
青蒿素等4种中草药抑制出血热病毒的实验研究. 郑宣鹤，唐晓鹏，苏先狮.湖南医科大学学报，第18卷第2期. 1993 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112294795A (zh) * 2020-11-17 2021-02-02 北京化工大学 蒿甲醚在治疗和预防柯萨奇病毒感染中的应用
CN112294795B (zh) * 2020-11-17 2022-03-29 北京化工大学 蒿甲醚在治疗和预防柯萨奇病毒感染中的应用

Also Published As

Publication number Publication date
AU2003287259A8 (en) 2004-06-07
WO2004041176A2 (en) 2004-05-21
US20050059647A1 (en) 2005-03-17
ATE473745T1 (de) 2010-07-15
DE60333392D1 (de) 2010-08-26
CA2501584A1 (en) 2004-05-21
WO2004041176A3 (en) 2004-10-07
JP2006504787A (ja) 2006-02-09
CA2501584C (en) 2009-03-10
JP4594734B2 (ja) 2010-12-08
PT1585524E (pt) 2010-10-19
US7842719B2 (en) 2010-11-30
AU2003287259A1 (en) 2004-06-07
EP1585524A4 (en) 2007-10-10
CN1711091A (zh) 2005-12-21
ES2348536T3 (es) 2010-12-09
EP1585524B1 (en) 2010-07-14
EP1585524A2 (en) 2005-10-19

Similar Documents

Publication Publication Date Title
CN100430061C (zh) 内过氧化物在制备治疗由黄病毒科病毒(包括丙型肝炎病毒、牛病毒性腹泻病毒和猪瘟病毒)引起的感染的药物中的应用
US20110206636A1 (en) Use of Endoperoxides for the Treatment of Infections Caused by Flaviviridae, Including Hepatitis C, Bovine Viral Diarrhea and Classical Swine Fever Virus
EP3900717B1 (en) Vidofludimus for use in the treatment or prevention of viral diseases
EP3785718B1 (en) Pharmaceutical composition for prevention or treatment of flavivirus infectious disease
CN115197231B (zh) 广谱抗病毒中药单体小檗胺及其应用
JP2007099747A (ja) トリインフルエンザ感染の治療
PL190505B1 (pl) Kompozycja farmaceutyczna i sposób jej wytwarzania
CA2465062C (en) Preventive and/or therapeutic agent for viral infection
WO2022079205A1 (en) Use of ifn-alpha polypeptides for the treatment of coronavirus infections
CN110664988B (zh) H-Lys-Trp-Lys-OH在制备抗牛肠道病毒药物中的应用
EP2683369B1 (en) Multiantivirus compound, composition and method for treatment of virus diseases
CN112805027A (zh) 一种抗新冠病毒感染的药物、食物与应用
CN103096885B (zh) 不饱和脂肪酸用于抑制病毒复制和/或感染的用途
CN111329859B (zh) 叶绿素铜钠盐在制备用于抗肠道病毒的药物中的应用
RU2172631C2 (ru) Индуктор интерферона пролонгированного действия
TWI798578B (zh) 棘白菌素類化合物於治療黃病毒感染症的用途
KR20230052615A (ko) 글리시리진 및 항바이러스제를 포함하는 나노 입자, 이를 포함하는 바이러스 감염증의 예방 또는 치료용 약제학적 조성물 및 이의 제조 방법
TW202335673A (zh) 一種化合物tsyi-zac用於抑制登革熱病毒感染及其醫藥治療用途
BG65190B1 (bg) Средство за химиотерапия и химиопрофилактика на флавивирусни инфекции
CN120960185A (zh) 麝香酮在制备病毒抑制剂中的应用
HK40062780A (en) Vidofludimus for use in the treatment or prevention of viral diseases
AU2020303322A1 (en) Pharmaceutical composition comprising a colloidal dispersion and methods and uses thereof
HK1067944A (en) Preventives/remedies for viral infection

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20081105

Termination date: 20121029